Evidence map›Paper›PMID 35608811›Full record

ArticlePituitary2022

W A Bashari, M van der Meulen, J MacFarlane, D Gillett, R Senanayake, L Serban, A S Powlson, A M Brooke, D J Scoffings, J Jones and 13 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06701838 (Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06701838 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease

TypeobservationalSponsorImperial College LondonRan2024 to 2026Enrolled15ConditionsCushing&#39, s Disease, Hypercortisolism, Pituitary AdenomaArms11C-Methionine PET/CT
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  2. Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Review
  4. The clinical value of [Pituitary · 2026
    Observational
  5. Article
  6. The Use of [Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Clinical use of [Pituitary · 2024
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 1 country.

W A BashariCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
M van der MeulenCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
J MacFarlaneCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
D GillettCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
R SenanayakeCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
L SerbanCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
A S PowlsonCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
A M BrookeMacleod Diabetes and Endocrine Centre, Royal Devon and Exeter Hospital, Exeter, UK.
D J ScoffingsDepartment of Radiology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
J JonesDepartment of Radiology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
D G O'DonovanDepartment of Neuropathology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
J TysomeDepartment of Otolaryngology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
T SantariusDepartment of Neurosurgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
N DonnellyDepartment of Otolaryngology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
I BorosWolfson Brain Imaging Centre, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
F AigbirhioWolfson Brain Imaging Centre, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
S JefferiesDepartment of Oncology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
H K CheowCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
I A MendichovszkyCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
A G KoliasDepartment of Neurosurgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
R MannionDepartment of Neurosurgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
O KoulouriCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
M GurnellCambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. mg299@medschl.cam.ac.uk.
Addenbrooke's Hospital · GBNational Institute for Health Research · GBUniversity of Cambridge · GBWellcome/MRC Institute of Metabolic Science · GBRoyal Devon and Exeter Hospital · GB

Funding

NIHR Cambridge Biomedical Research Center BRC-1215-20014
6 · The paper itself

Abstract

purposeTo assess the potential for PATIENTS AND

methodsThirteen patients with pituitary microprolactinomas, and who were intolerant (n = 11) or resistant (n = 2) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET/MR

resultsIn all 13 patients Met-PET/MR

conclusionsIn patients with dopamine agonist intolerance or resistance, and indeterminate pituitary MRI, molecular (functional) imaging with Met-PET/MR

Indexed as

AdenomaHyperprolactinemiaPituitary NeoplasmsProlactinomaDopamine AgonistsHumansMethioninePositron-Emission TomographyDopamine AgonistsMethionine11C-methionine PETDopamine agonist intolerance/ resistanceMicroprolactinoma

Identifiers

PMID35608811
PMCPMC9345820
OpenAlexW4282930736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.